INTRODUCTION
The management of type 2 diabetes mellitus (T2DM) requires a multifactorial treatment approach that addresses clinical and psychosocial aspects of this chronic illness.
There are multiple therapeutic classes of oral and injectable treatments available for T2DM.
Treatment should be selected and individualized based on specific patient requirements for glycemic control, and patient preferences, characteristics, and susceptibilities to side effects, including potential for weight gain and hypoglycemia [1] .
Glucagon-like peptide (GLP)-1 receptor agonists are a relatively new class of medications for T2DM. Randomized clinical trials (RCTs) have shown that exenatide twice daily (BID), the first approved GLP-1 receptor agonist, provided glucose-lowering efficacy similar to that of insulin glargine and biphasic insulin aspart and that, in contrast with insulins, it was associated with weight loss [2] [3] [4] . Although RCTs provide the least biased estimates of efficacy, data derived from a trial setting have limited generalizability to routine clinical practice, where treatment may be initiated in patients dissimilar to those enrolled in the clinical trial program, or it may perform differently than in a controlled setting and where modification of therapy is more common [5, 6] . In addition, RCTs remove the most important factor affecting the way in which medical care is actually delivered: doctors and patients acting as individuals with differing beliefs, needs, and priorities. Welldesigned prospective observational studies in clinical practice are therefore necessary to provide a holistic understanding of treatment [7, 8] and to enhance the evidence upon which the management of T2DM is based [1] . To date, limited information concerning the real-life use of GLP-1 receptor agonists in Europe is available and it is not clear how GLP-1 receptor agonists compare with initial insulin therapy in real life.
For example, it has not been clear which patients are prescribed these agents or initial insulin treatment, how long GLP-1 receptor agonists are taken, how patients who eventually stop these agents or modify them by using different combinations of antidiabetes treatments are managed afterwards, and finally, why some patients stop or modify these therapies. Data are limited concerning the effectiveness, safety, and associated resource use of both GLP-1 receptor agonists and insulin.
CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy; NCT00635492) was a 24-month prospective observational study conducted in multiple European countries. It was designed to assess the time to a significant treatment change after patients initiated their first injectable, glucose-lowering therapy in clinical practice and thereby evaluate patterns of initial injectable therapy usage and outcomes in clinical practice in patients with T2DM. Significant treatment change was defined as at least one of the following: discontinuation of any exenatide BID/insulin initiated at baseline; addition of a new medication (any route of administration) for the treatment of T2DM; a change in the number of times insulin is administered per day; or substitution of a human insulin for an analog insulin or vice versa (not including switching between brands of the same class/type of insulin). Details of the characteristics of patients initiating the two treatment strategies have been described [9] . This paper reports observed treatment changes and clinical outcomes during the study.
PATIENTS AND METHODS

Design and Patients
CHOICE is a prospective, multinational, noninterventional observational study that recruited patients from six European countries (Denmark, Belgium, France, Germany, Greece Matthaei et al. [9] .
Analysis
Sample Size Justification
Monte Carlo simulation was used to calculate sample size, and assumed patient dropout rates of 10-15% per year and a median time to significant treatment change of 9.0 months for the exenatide BID cohort and 8.6 months for the insulin cohort [10; data on file]. Based on this, the study aimed to recruit a maximum of 800 patients per country/country group, with approximately 60% initiating insulin and 40%
initiating exenatide BID. The insulin cohort was to be larger than the exenatide BID cohort because of the greater variability in the former cohort (linked to use of different insulin regimens).
Statistical Analysis
All patients who provided consent to release information, fulfilled the study entry criteria ('eligible patients'), and had a case report form summary page signed by an investigator were included in the analysis. Analyses of the clinical endpoints were conducted on the eligible population in two ways: (1) according to the cohort (insulin or exenatide BID) that they were in at baseline ('initiators analysis'); and (2) using the groups of patients with no significant treatment change (using the original study definitions) at study end or at the time of early discontinuation (this could be at any time) from the study ('persisters analysis'). The persisters analysis was added post hoc due to the observed incidence of treatment changes. Early discontinuation occurred when a patient was lost to follow-up, withdrew from the study, or died at, or before, the 24-month visit. Propensity score analysis was used to estimate the probability that a patient would be assigned to a treatment group based on baseline characteristics [11] . Scores were derived from baseline data using logistic regression (0.10 threshold for between-cohort differences). Missing data were imputed with the overall mean or median for continuous variables, as well as the most frequent category for categorical variables. Patients were matched 1:1 by country based on the propensity score and optimal matching to identify matched subsets from the two cohorts.
Cox regression models were applied within each cohort to explore the association of 
RESULTS
A total of 2,515 patients were recruited; 2,388 (95.0%) were eligible for the 24-month analysis;
1,114 in the exenatide BID cohort and 1,274 in the insulin cohort (these patients were included in the initiators analyses). Overall, 23.5% of the eligible patients discontinued the study at or before 24 months (reasons are shown in Fig. 1 ).
Demographic and Clinical Characteristics
Overall, patients in the exenatide BID cohort tended to be younger and more obese, but had better glycemic control and fewer diabetes complications compared with the insulin cohort ( In the exenatide BID group, the proportion of enrolled patients experiencing treatment change was highest (20.8%) in the first 6 months post initiation, and lower thereafter (Fig. 2) . Throughout the study, the proportions of patients who had not had a significant treatment change at 6, 12, 18 and 24 months were 79.2%, 67.8%, 59.3% and 53.9%, respectively. Almost three-fourths of the first significant treatment changes were discontinuations, with the remainder mainly comprising the addition of oral antidiabetes medications ( Table 2 ).
In the insulin cohort, the proportions of enrolled patients who had a significant treatment change was also highest (22.1%) in the first 6 months post initiation, and then decreased during the remainder of the study (Fig. 2) . Throughout the study, the proportions of patients who had not had significant Change to the number of times insulin was administered per day NA 81 (6.4)
Substitution of a human insulin for an analog insulin or vice versa NA 0 (0)
BID twice daily, NA not applicable a Where two categories of significant treatment change occurred simultaneously, the categories were ordered:
(1) discontinuation of any injectable medication initiated at baseline; (2) addition of new medication; (3) change to the number of times insulin was administered per day; (4) substitution of a human insulin for an analog insulin or vice versa 
Clinical Outcomes and Adverse Events
Exenatide BID Improvements were observed in HbA 1c in the exenatide BID cohort (Table 5 ). When Only one reason could be selected by health care professionals (Table 5 ). In addition, mean weight was significantly reduced in the exenatide BID cohort by 24 months ( (Fig. 4) . Severe hypoglycemia (requiring third-party assistance or a hospital Patients could add/discontinue more than 1 treatment throughout the study BID twice daily, DPP-IV dipeptidyl peptidase-IV, NA not applicable, OAD oral antidiabetes drug, SU sulfonylurea, TZD thiazolidinedione (Table 5 ). However, mean weight was significantly increased in the insulin cohort ( Overall, 36.8% of patients who initiated insulin (33.3% of persisters) experienced at least one episode of hypoglycemia (Fig. 4) . Severe hypoglycemia (requiring third-party assistance or a hospital visit) was experienced by 8.4% of insulin initiators (76 patients) and 5.7% of persisters (34 patients). During the 3 months before the baseline visit, patients in Overall, 5.3% of patients in the insulin cohort experienced GI events (most commonly abdominal pain in 2.5% of patients).
Propensity-Matched Subgroup
Propensity matching of baseline patient and disease characteristics identified 619 pairs of patients who could be compared (51.8% of the total sample). These patients had a mean (SD) duration of diabetes of 9.1 (6.3) years [9.0 (6.0) years for the exenatide BID group and 9.2 (6.6) years for the insulin group]; other baseline characteristics are summarized in Table 6 . In this propensity-matched subgroup, patients in the exenatide BID group had significantly greater mean (SD) weight loss (p\0.0001) and a lower incidence of patientrecalled hypoglycemia (p\0.0001) than the insulin group during the study (Table 6) 
DISCUSSION
CHOICE was a prospective observational study designed to evaluate patterns of exenatide BID and insulin usage and outcomes in clinical practice in multiple European countries. In this study, 42.2% of patients who initiated exenatide BID and 36.0% who initiated insulin had a significant treatment change during the 24 months after these treatments were started. In another European study of insulin initiation [13] , rates of treatment change in the 24-month period following insulin initiation were 2.9-19.4% (depending on insulin regimen). It is unclear why the results of that study differed from our findings. In CHOICE, patients in the two treatment cohorts were substantially different, with the exenatide BID cohort tending to have a younger age, higher body weight, BMI, waist circumference and diastolic blood pressure, lower total and low-density lipoprotein (LDL)-cholesterol levels, a shorter time since diabetes diagnosis, and better glycemic control at baseline than patients in the insulin cohort [9] . Therefore, we were unable to compare the clinical findings for the total exenatide BID and insulin cohorts.
Time to significant treatment change was chosen as the primary outcome of this study, because it was anticipated that patients prescribed exenatide BID would continue to move through the available treatment algorithms until insulin was initiated. A combination of factors, including glycemic control and tolerability, were believed to influence treatment changes or control is associated with increased morbidity [14] , so the time taken to modify treatment in response to poor control or unwanted adverse effects for patients initiated on exenatide BID or insulin is of interest. We found that the proportion of enrolled patients with treatment change in the exenatide BID group was highest in the first 6 months of the study and then decreased throughout the remainder of the study. The majority of the first significant treatment changes in this cohort were discontinuations, with the remainder mainly comprising the addition of oral antidiabetes medications. The most frequent reasons for treatment change were inadequate response and adverse events. This is consistent with the results of a recently published clinical trial [15] . 
Post hoc analyses of CHOICE identified
Continuous data are means (SD); changes were compared between the 2 matched subgroups using paired t tests BID twice daily, GI gastrointestinal, In the insulin cohort, the proportions of patients with significant treatment change were also highest in the first 6 months of the study and then decreased throughout the remainder of the study. The most common first significant treatment change for patients on insulin was the addition of a new injectable antidiabetes medication, with most patients requiring upgraded therapy to a more intensive regimen.
When compared with baseline initiation of long-acting insulin only, patients initiating basal-bolus insulin or mixtures were less likely to have significant treatment change, and those initiating short-acting insulin only were more likely to have significant treatment change (Fig. 3 ). These observations are in line with results of the 4T trial, which indicated that, after 1 year, patients initially treated only with long-acting insulin were more likely to require a change in treatment (additional dose or addition of a second insulin) than patients initially receiving basal-bolus insulin [16] and, after 3 years, patients initiated only on shortacting or long-acting insulin required higher insulin doses than those initiated on basal-bolus insulin [17] . However, patients initiating only short-acting insulin in the 4T trial were less likely to require addition of another type of insulin than patients initiated on long-acting insulin after 1 year [16] . 
